Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study - PubMed
8 hours ago
- #NSCLC
- #Phase Ib Study
- #Targeted Therapy
- Study evaluates izalontamab brengitecan (iza-bren) in NSCLC with actionable genomic alterations outside classical EGFR mutations.
- 83 patients enrolled in four cohorts: EGFR exon20ins/nonclassical, HER2, KRAS/BRAF/MET, and ALK/ROS1/RET/NTRK mutations.
- Common grade ≥3 TRAEs: thrombocytopenia (51.8%), anemia (44.6%), neutropenia (43.4%). Nonhematologic TRAEs: nausea (49.4%), asthenia (45.8%), stomatitis (44.6%), diarrhea (38.6%).
- Confirmed ORR: 39.7%, DCR: 85.9%. Median PFS: 7.0 months. EGFR exon20ins/nonclassical mutations had ORR 69.2%, median PFS 10.5 months; HER2-mutant cohort ORR 52.9%, median PFS 7.5 months.
- iza-bren showed promising antitumor activity and manageable safety in pretreated NSCLC patients with diverse GAs outside classical EGFR mutations.